|
|
|
|
|
非在研适应症- |
最高研发阶段早期临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Single Arm, Open Lable and Single Site Early Phase I Clinical Trial to Evaluate the Safety, Cell Kinetics and Initial Efficacy About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects
An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects. To evaluate the tolerability and safety of different doses of HEC-016 CAR-T cell injections in patients with advanced gastric / esophagogastric junction adenocarcinoma and pancreatic cancer, to observe dose limiting toxicity (DLT), to determine the maximum tolerated dose (MTD) and to recommend the regimen for subsequent clinical trials.
100 项与 深圳市罗湖区人民医院 相关的临床结果
0 项与 深圳市罗湖区人民医院 相关的专利(医药)
100 项与 深圳市罗湖区人民医院 相关的药物交易
100 项与 深圳市罗湖区人民医院 相关的转化医学